Novo Nordisk A/S (NVO) Stock Forecast
NVO analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.29 / 5 from 14 analysts
- Price target
- $45.81 average of analyst targets
- Upside to target
- +18.0% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.81
- 52-week range
- $35.29 – $63.98
NVO analyst ratings
14 analystsNumber of analysts at each rating.
NVO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NVO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.62 | $4.01 | $5.28 | $4.50 | +2.7% | 3 |
| Current fiscal year (2026) | $22.39 | $21.01 | $24.25 | $23.03 | −2.8% | 8 |
| Next fiscal year (2027) | $22.89 | $21.73 | $23.74 | $22.39 | +2.2% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NVO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $73.79B | $71.19B | $78.49B | −1.6% | 12 |
| Current fiscal year (2026) | $301.95B | $272.68B | $334.98B | −2.3% | 27 |
| Next fiscal year (2027) | $305.92B | $286.94B | $343.47B | +1.3% | 25 |
NVO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NVO revenue: reported and forecast
NVO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.79 | $5.13 | $5.11 | $4.83 | $4.62 | −3.5% | 0 up · 2 down |
| Current fiscal year (2026) | $21.86 | $23.08 | $23.24 | $22.53 | $22.39 | +2.4% | 1 up · 2 down |
| Next fiscal year (2027) | $22.02 | $21.85 | $21.91 | $22.09 | $22.89 | +3.9% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NVO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NVO beat in 9 of 12.
What analysts expect from NVO
14 analysts cover Novo Nordisk A/S; their consensus rating is hold (3.29 on a 1–5 scale, where 5 is a strong buy). The average price target is $45.81, 18.0% above the latest close of $38.83. Analysts expect earnings of $22.39 per share for 2026, −2.8% from a year earlier. For 2027 the average estimate is $22.89 per share on revenue of $305.9 billion. Novo Nordisk A/S beat the EPS estimate in 9 of the last 12 quarters.
Related: NVO income statement, NVO key metrics, NVO chart. See the NVO stock overview for the latest quote and news.
NVO forecast FAQ
What is Novo Nordisk A/S's price target?
The average analyst price target for Novo Nordisk A/S is $45.81, 18.0% above the latest close of $38.83.
Is Novo Nordisk A/S a buy, hold or sell?
Of 14 analysts covering Novo Nordisk A/S, 3 rate it a strong buy, 0 a buy, 10 a hold, 0 a sell and 1 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Novo Nordisk A/S's EPS forecast?
Analysts forecast $22.39 per share for 2026 (range $21.01 to $24.25); for 2027 the estimate is $22.89.
What is Novo Nordisk A/S's revenue forecast?
The average revenue estimate for 2026 is $302.0 billion, growth of −2.3%; for 2027 it is $305.9 billion.
When does Novo Nordisk A/S report earnings?
Novo Nordisk A/S is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $0.81.
Does Novo Nordisk A/S usually beat earnings estimates?
Novo Nordisk A/S reported EPS at or above the analyst estimate in 9 of the last 12 quarters.